Skip to content
DataLookout
Menu

COPILOTNCT07469501

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 1 month later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from May 2027 to Jul 2028 Show 4 more changesShow less
    • Start date: Jun 2026 to Nov 2026
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: 16 to 1
    • Publications: details revised at 2 of 2 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Continuous retention in outpatient buprenorphine treatment by day 90
Timeframe: 90 days
Self-reported protocol satisfaction at day 7
Timeframe: 7 days

Secondary (1)

Successful buprenorphine initiation within first 7 days

Arms and interventions

Low-dose initiation (LDI)Active comparator

Participants start 0.5mg sublingual buprenorphine (Subutex) and gradually increase by 0.5-1.0mg daily for 7 days

Direct-to-inject (DTI)Experimental

Participants receive 8-32mg long-acting injectable buprenorphine (Brixadi or Sublocade) on day 1, followed by monthly injections as discussed with the provider

Drugs: Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)

Sites

1 site in 1 country

  • San Francisco Outpatient Buprenorphine Induction ClinicSan Francisco, California, United States